General form of registration statement for all companies including face-amount certificate companies

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- 2. Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

11. Stockholders' Equity (Details Narrative)

v3.5.0.2

11. Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
11. Stockholders' Equity (Details Narrative) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Prepayment on acquisition	$ 0		$ 0		$ 3,744,517	$ 0
Research and development expense	$ 2,205,213	$ 555,740	$ 2,634,494	$ 1,590,823	$ 3,434,016	6,323,896
Baxalta [Member]
Stock issued for equity investment, shares					324,097
Stock issued for equity investment, amount					$ 10,000,000
Non-Employee Director [Member]
Warrant expense						$ 240,000
SynBio Partner Warrants [Member] \| SynBio 2014 Warrant [Member]
Warrant issued						9,697
Warrants exercised					0	0
SynBio 2014 Warrant [Member]
Warrant issued						204,394
Warrant exercise price per share						$ 25.41
Warrants exercised					0	0
Serum Institute 2014 Warrant [Member]
Warrant issued						96,970
Fair value of warrant at date of grant						$ 480,000
Warrant exercise price per share						$ 25.41
Serum Institute 2014 Warrant [Member] \| Serum Institute Partner Warrants [Member]
Warrant issued						4,849
Fair value of warrant at date of grant						$ 24,000
Warrants exercised					0	0
Warrant expense					$ 706,500	$ 0
Consultant [Member]
Warrant issued					25,243
Fair value of warrant at date of grant					$ 227,000
Warrant exercise price per share					$ 25.41
Warrant expense					$ 227,000
Asset Purchase Agreement [Member]
Prepayment on acquisition					$ 3,744,517
Issuance of common stock in connection with pending asset acquisition, shares					333,334
Non-Employee Director [Member]
Warrant issued						48,485
Fair value of warrant at date of grant						$ 240,000
Warrant exercise price per share						$ 25.41

- Definition

Adjustment for noncash service expenses paid for by granting of warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

+ Details

Name:	us-gaap_AdjustmentOfWarrantsGrantedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Prepayment on acquisition

+ References

No definition available.

+ Details

Name:	xbio_PrepaymentOnAcquisition
Namespace Prefix:	xbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Stock issued for equity investment

+ References

No definition available.

+ Details

Name:	xbio_StockIssuedForEquityInvestment
Namespace Prefix:	xbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Stock issued for equity investment, shares

+ References

No definition available.

+ Details

Name:	xbio_StockIssuedForEquityInvestmentShares
Namespace Prefix:	xbio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Warrants exercised

+ References

No definition available.

+ Details

Name:	xbio_WarrantsExercised
Namespace Prefix:	xbio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xbio_BaxaltaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xbio_NonEmployeeDirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=xbio_SynBioPartnerWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=xbio_Synbio2014WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=xbio_Synbio2014WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=xbio_SerumInstitute2014WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=xbio_SerumInstitutePartnerWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=xbio_ConsultantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=xbio_APAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=xbio_NonEmployeeDirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: